[EN] CRYSTALLINE FORM OF FUSED PYRIDINE DERIVATIVE'S MALEATE AND USES THEREOF<br/>[FR] FORME CRISTALLINE D'UN MALÉATE DÉRIVÉ D'UNE PYRIDINE FUSIONNÉE ET SES UTILISATIONS
申请人:BETTA PHARMACEUTICALS CO LTD
公开号:WO2017012539A1
公开(公告)日:2017-01-26
The compound of Formula I, the crystalline form thereof, and methods of preparing and using them are provided.
[EN] MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF<br/>[FR] DÉRIVÉS DE PYRIDONE MULTISUBSTITUÉS ET LEUR UTILISATION MÉDICALE<br/>[ZH] 多取代吡啶酮类衍生物及其在医药上的应用
CRYSTALLINE FORM OF FUSED PYRIDINE DERIVATIVE'S MALEATE AND USES THEREOF
申请人:Betta Pharmaceuticals Co., Ltd.
公开号:EP3292115A1
公开(公告)日:2018-03-14
PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
申请人:Incyte Corporation
公开号:EP3436461A1
公开(公告)日:2019-02-06
Compounds and method for the prevention and treatment of diabetic retinopathy
申请人:——
公开号:US20030211981A1
公开(公告)日:2003-11-13
The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine
pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.